Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit from M&A

TL;DR

Alkermes and Illumina face FDA hurdles while announcing M&A deals in the healthcare sector.

Transcript

Shannon Jones: Welcome to Industry Focus, the show that dives into a different sector of the stock market every day. Today is Wednesday, November 7th. We're talking Healthcare. I'm your host, Shannon Jones, and I am joined via Skype by healthcare specialist and all-around good guy, Todd Campbell. Todd, how are you? Todd Campbell: I'm doing great, S... Read More

Key Insights

• 💪 Regulatory hurdles impact Alkermes' ALKS 5461 approval, highlighting the need for strong efficacy data.
• 🫠 Illumina's acquisition of PacBio aims to combine short-read and long-read gene sequencing technologies for competitive market advantages.
• 🍵 Alkermes handles setbacks by focusing on its existing revenue-generating products like Vivitrol and Aristada.
• 🫠 Illumina's move into the long-read sequencing market signifies a strategic shift towards expanding genomic data analysis capabilities.
• 😀 Both companies face challenges and opportunities in the evolving healthcare landscape, showcasing the importance of regulatory compliance and strategic planning.
• ❓ PacBio's potential growth in the gene sequencing market aligns with Illumina's market dominance and future prospects.
• ❓ Alkermes seeks to diversify its pipeline with upcoming drug candidates like 3831 for schizophrenia treatment, offsetting potential setbacks from ALKS 5461.

Questions & Answers

Q: What led to Alkermes's FDA panel rejection for ALKS 5461?

Alkermes failed to provide substantial evidence of efficacy for its depression drug, leading to an overwhelming vote against its approval by the Advisory Committee.

Q: How does Illumina aim to benefit from acquiring PacBio in the gene sequencing market?

Illumina plans to combine short-read and long-read sequencing technologies to enhance its genomic data analysis capabilities and maintain a competitive edge in the evolving gene sequencing market.

Q: What strategic reasons led Alkermes to pursue ALKS 5461 despite regulatory uncertainties?

Alkermes aimed to address the unmet needs in depression treatment by introducing a novel approach with ALKS 5461, using a unique combination of an opiate and a counteracting compound to potentially improve efficacy and safety.

Q: What should investors watch for in 2019 regarding the Alkermes and Illumina developments?

Investors should monitor the progress of ALKS 5461 approval, PacBio's product launches, regulatory approval for the acquisition deal, and potential synergies in manufacturing and cost reduction efforts.

Summary & Key Takeaways

• Alkermes faces FDA panel rejection for its depression drug, ALKS 5461, due to lack of efficacy evidence.

• Illumina acquires PacBio to combine short-read and long-read gene sequencing technologies for competitive advantages.

• Both companies anticipate strategic moves in the healthcare sector amid regulatory challenges.